ライフサイエンスコーパス: placebo-controlled study

1 III, randomized, double-masked, multicenter, placebo-controlled study.

2 II in case studies, cohort studies, and one placebo-controlled study.

3 Randomized, double-blind, placebo-controlled study.

4 o Bolivian Leishmania (v.) braziliensis in a placebo-controlled study.

5 This was a randomized placebo-controlled study.

6 , prospective, 1:1 randomized, double-blind, placebo-controlled study.

7 eers underwent a randomized, double-blinded, placebo-controlled study.

8 EBV shedding in a randomized, double-blind, placebo-controlled study.

9 d in a phase I, double-blind, multiple-dose, placebo-controlled study.

10 lled in a 6-month, randomised, double-blind, placebo-controlled study.

11 igation was a within-subjects, double-blind, placebo-controlled study.

12 , an event-driven, randomized, double-blind, placebo-controlled study.

13 in a randomized, three-armed, double-blind, placebo-controlled study.

14 cts in a randomized, four-way, double-blind, placebo-controlled study.

15 the safety and efficacy of sipuleucel-T in a placebo-controlled study.

16 tients with moderate-to-severe OA pain, in a placebo-controlled study.

17 week, multicenter, double-blind, randomized, placebo-controlled study.

18 onth, multicenter, randomized, double-blind, placebo-controlled study.

19 ed statistically in a post hoc analysis of a placebo-controlled study.

20 This was a randomized, double-blind, placebo-controlled study.

21 was a multicenter, randomized, double-blind, placebo-controlled study.

22 ients from healthy donors in a double-blind, placebo-controlled study.

23 horea, was well tolerated in a double-blind, placebo-controlled study.

24 were investigated in a pilot, double-blind, placebo-controlled study.

25 se of patients treated with ivacaftor in the placebo-controlled study.

26 that of patients who received placebo in the placebo-controlled study.

27 nts who had received active treatment in the placebo-controlled study.

28 eart failure attended a series of randomized placebo-controlled studies.

29 se in two parallel, identical, double-blind, placebo-controlled studies.

30 ed recent-onset AF and was well tolerated in placebo-controlled studies.

31 ted in a series of randomized, double-blind, placebo-controlled studies.

32 ent will be determined by ongoing randomized placebo-controlled studies.

33 > or = 65 years, using data pooled from two placebo-controlled studies.

34 systematic evaluation in large, randomized, placebo-controlled studies.

35 that seen with the same drugs and dosages in placebo-controlled studies.

36 In a randomized, double-blind, placebo-controlled study, 12 subjects with asthma (FEV1,

37 In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipola

38 AND PARTICIPANTS: In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age,

39 In this double-blind, randomized, crossover, placebo-controlled study, 22 subjects with DSM-IV treatm

40 -month dose-response randomized double-blind placebo-controlled study, 221 polysensitized subjects wi

41 e II, multicentre, randomised, double-blind, placebo-controlled study, 249 patients with RRMS, aged 1

42 an international, randomized, double-blind, placebo-controlled study, 253 patients with first ST-seg

43 In this double-blind, placebo-controlled study, 290 subjects were randomized t

44 In a double-blind, placebo-controlled study, 32 subjects with major depress

45 In a double-blind placebo-controlled study, 36 female patients with IBS-C

46 In this double-blind, placebo-controlled study, 40 healthy male subjects were

47 In this double-blind, randomized, placebo-controlled study, 55 children, 5 to 11 years of

48 In a randomized double-blind placebo-controlled study, 56 patients with moderate-seve

49 In this double-blind, placebo-controlled study, 57 patients with RP secondary

50 In a randomized, double-blind, placebo-controlled study, 60 patients with fibrotic IIP

51 In a 12-week, double-blind, placebo-controlled study, 60 treatment-resistant childre

52 In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years

53 this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut al

54 s.In this 12-wk, double-blinded, randomized, placebo-controlled study, 76 vegans received either a pl

55 In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-

56 In this prospective randomized placebo-controlled study, a single subcutaneous dose of

57 In this phase III, randomised, double-blind, placebo-controlled study, adults from 63 sites in 23 cou

58 In a randomized, blinded, placebo-controlled study, adults were challenged with mo

59 This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical

60 ransmembrane conductance regulator (CFTR) in placebo-controlled studies and patients aged 6-11 years

61 d onto a phase III, multicenter, randomized, placebo-controlled study and administered placebo or DA

62 luded 2 studies: a randomized, double-blind, placebo-controlled study and an open-label extension stu

63 re of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these patients rece

64 dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, ran

65 Results from large scale placebo-controlled studies are awaited.

66 athic pulmonary fibrosis, although data from placebo-controlled studies are lacking.

67 More placebo-controlled studies are needed in this area to de

68 Placebo-controlled studies are needed to confirm whether

69 -related food allergy is not clear, and more placebo-controlled studies are needed.

70 quate follow-up and in particular randomized placebo-controlled studies are required to confirm these

71 This placebo-controlled study assessed the effects of the onc

72 ofile of REG1 in a randomized, double-blind, placebo-controlled study, assigning 50 subjects with cor

73 nter, prospective, randomized, double-blind, placebo-controlled study at 2 tertiary medical centers o

74 We did this double-blind, placebo-controlled study at 35 hospitals in Canada, Fran

75 We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries

76 is randomised, double-blind, parallel-group, placebo-controlled study at 49 hospitals in seven Europe

77 We did a phase 2, randomised, double-blind, placebo-controlled study at 51 centres in the USA, Canad

78 A randomized, placebo-controlled study based on preclinical and clinic

79 In this first placebo-controlled study, canakinumab was effective in p

80 ulin regulation of lipolysis.A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosape

81 An 8-week, randomized, double-blind, placebo-controlled study compared the safety and efficac

82 disease onset in a total of four randomized, placebo-controlled studies conducted in rabbits and monk

83 Double-blind, placebo-controlled study conducted among 380 patients wh

84 rbamazepine, was assessed in a double-blind, placebo-controlled study conducted from September 2014 t

85 Double-blind, randomized placebo-controlled study conducted in 29 centers in the

86 ere assessed in a multicentre, double-blind, placebo-controlled study conducted in 483 patients with

87 were included in a randomized, double-blind, placebo-controlled study conducted in Switzerland betwee

88 A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the Un

89 This randomized, double-blind, placebo-controlled study consisted of 2 parts.

90 This randomized, double-blind, placebo-controlled study consisted of 2 test days during

91 In a double-blind placebo-controlled study, critically ill intubated patie

92 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) wit

93 fibrate (FFB) (160 mg/day) in a single-blind placebo-controlled study design.

94 ge chamber using a monocenter, double-blind, placebo-controlled study design.

95 cularis monkeys were used in a double-blind, placebo-controlled study design.

96 ye Disease Study 2 (AREDS2) is a randomized, placebo-controlled study designed to determine whether s

97 RN-HIV) trial is a randomized, double-blind, placebo-controlled study, designed to investigate the ef

98 T was a three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA,

99 IT2 was a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countr

100 In a randomized, placebo-controlled study, either protein C or placebo wa

101 In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 ye

102 Placebo-controlled studies enrolled cohorts at low risk

103 III, double-blind, randomized, multicenter, placebo-controlled study, established the efficacy and s

104 (ACT)-1 and ACT-2 randomized, double-blind, placebo-controlled studies evaluated infliximab inductio

105 A multicenter, randomized, double-blind, placebo-controlled study evaluated 3 regimens of grass a

106 A randomized, double-blind, placebo-controlled study evaluated an adjuvanted bivalen

107 This randomized, double-blind, placebo-controlled study evaluated the effects of oral l

108 This phase II randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorin

109 This phase 1/2, randomized, placebo-controlled study evaluated the immunogenicity an

110 multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and effica

111 uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity

112 was a multicenter, randomized, double-blind, placebo-controlled study evaluating quinapril 80 mg/day,

113 TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sit

114 To conduct a robust, double-blind, placebo-controlled study examining the effects of tumor

115 GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these r

116 isorder in children, and the lack of masked, placebo-controlled studies for those therapies currently

117 s, and carried out a double-blind randomized placebo-controlled study for 16 weeks, followed by an op

118 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepre

119 To date, no double-blind, placebo-controlled studies have been carried out that sp

120 Although a profusion of explanatory placebo-controlled studies have contributed little to de

121 Placebo-controlled studies have not been conducted to ev

122 Several randomised placebo-controlled studies have shown that UDCA improves

123 In placebo-controlled studies in children >1 year of age, o

124 Three independent placebo-controlled studies in healthy men were conducted

125 o observed in low dose-controlled studies vs placebo-controlled studies in ineffective and intermedia

126 We performed a blinded, randomized and placebo-controlled study in 11 conscious patients (nine

127 ve days in a single-blind (patients masked), placebo-controlled study in 12 men with clinically stabl

128 Duloxetine was administered in a randomized, placebo-controlled study in 15 healthy volunteers.

129 This was a double-blind, placebo-controlled study in 20 volunteers.

130 leagues reported a randomised double-blinded placebo-controlled study in 291 infants aged 12-16 weeks

131 is a multicentre, randomised, double-blind, placebo-controlled study in 3323 women with stage 1-3 br

132 Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of b

133 This was a randomized, double-blind, placebo-controlled study in 47 healthy volunteers of dos

134 We conducted a randomized, double-blind, placebo-controlled study in 77 subjects with diabetic ne

135 was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma

136 did a multicentre, double-blind, randomised, placebo-controlled study in four hospitals in Kenya (two

137 In a subsequent double-blind, placebo-controlled study in healthy volunteers, we aimed

138 Furthermore, in a randomized, double-blind, placebo-controlled study in man, theobromine suppresses

139 , an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for he

140 , and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced non-s

141 This was a randomized, placebo-controlled study in patients with International

142 ticentre, phase 3, randomised, double-blind, placebo-controlled study in patients with tuberous scler

143 We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behc

144 This was a randomized, double-blind, placebo-controlled study in which 68 individuals were ra

145 The trial was a double-blind, placebo-controlled study in which 8290 patients were ran

146 nteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was a

147 a randomized, double-blind, counterbalanced, placebo-controlled study in which we administered the br

148 A double-blind, randomized, placebo-controlled study included 63 healthy female volu

149 e 2, multi-center, randomized, double-blind, placebo-controlled study included a 12-week treatment ph

150 e II, multicenter, randomized, double-blind, placebo-controlled study included the following: a 12-we

151 In three double-blind, placebo-controlled studies, intradermal avotermin (conce

152 The prospective, placebo-controlled study involved exclusively breastfed

153 atients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open

154 a from a series of randomized, double-blind, placebo-controlled studies involving subjects with unipo

155 TIENTS: A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with isch

156 this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evalu

157 RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriat

158 gnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsi

159 We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previou

160 Randomized, double-blind, placebo-controlled study (Measuring Effects on Intima-Me

161 In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castra

162 collected from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week

163 In a multicentre randomised double-blind placebo-controlled study, Munro Peacock and colleagues r

164 This randomized, placebo-controlled study (NCT00985725) enrolled 143 adul

165 Despite robust data from randomized placebo-controlled studies, no treatments are licensed s

166 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effe

167 Few placebo-controlled studies of antibiotics have been done

168 25, 2015, from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration

169 intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for a

170 ble for 40 subjects who have participated in placebo-controlled studies of drotrecogin alfa (activate

171 Results were integrated from 2 double-blind, placebo-controlled studies of ecallantide treatment for

172 e field is strongly supported by blinded and placebo-controlled studies of IL-5 and oral viscous bude

173 bility data from 2 double-blind, randomized, placebo-controlled studies of infliximab plus methotrexa

174 was pooled from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the t

175 We conducted a double-blind, placebo-controlled study of 119 adults with moderate to

176 med a randomized Phase I/II, observer-blind, placebo-controlled study of 12 healthy, H pylori-negativ

177 -day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with nonconstip

178 A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents

179 This was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 y

180 , and Participants: Multicenter double-blind placebo-controlled study of 260 nonneutropenic, nontrans

181 rformed a 10-week, randomized, double-blind, placebo-controlled study of 281 patients with mildly to

182 A randomized, double-blind, placebo-controlled study of 41 subjects genotypically af

183 med a randomized, double-blind, multicenter, placebo-controlled study of 420 patients with IBS-C give

184 We performed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarr

185 We conducted a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM pa

186 We did a double-blind, placebo-controlled study of a device-based non-specific

187 Multicenter, randomized, double-masked, placebo-controlled study of acetazolamide in 165 partici

188 We conducted a double-blind, randomized, placebo-controlled study of allergen-impermeable bed cov

189 A randomized, double-blind, placebo-controlled study of allergic and nonallergic pat

190 confirmed this prediction empirically with a placebo-controlled study of cholinesterase inhibition.

191 participants of a randomized, double-blind, placebo-controlled study of daclizumab (DZB) and mycophe

192 viously reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT

193 reported the results of a 1-y double-blind, placebo-controlled study of embryonic dopamine cell impl

194 costeroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, cort

195 We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry i

196 was a prospective, double-blind, randomized, placebo-controlled study of healthy infants aged 3-24 mo

197 We conducted a randomized, double-blind, placebo-controlled study of IPTp comparing the standard

198 We conducted a randomized, double-blind, placebo-controlled study of lebrikizumab, a monoclonal a

199 is the standard treatment, yet no randomized placebo-controlled study of medical IOP reduction has be

200 harmacotherapy, a large, recently completed, placebo-controlled study of methylphenidate for preschoo

201 his was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autisti

202 We conducted a double-blind, randomized, placebo-controlled study of nasal responses to live atte

203 rst year of life.A double-blind, randomized, placebo-controlled study of newborn infants assigned to

204 The authors conducted a randomized, placebo-controlled study of nicotine replacement therapy

205 This was a double-blind randomized placebo-controlled study of once-daily extended-release

206 ded this work in a randomized, double-blind, placebo-controlled study of patients with bipolar depres

207 We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular

208 In a placebo-controlled study of patients with IBS, a low FOD

209 e this issue, we performed a double-blinded, placebo-controlled study of rhAPC in a human model of en

210 least 2 weeks of a randomized, double-blind, placebo-controlled study of risperidone.

211 Report a double-blind, placebo-controlled study of rituximab in patients with a

212 s a multicenter, randomized, double-blinded, placebo-controlled study of tezosentan in patients with

213 atients who completed a 30-month randomized, placebo-controlled study of the effect of doxycycline on

214 We conducted a randomized, double-blind, placebo-controlled study of the effect of inhaled nitric

215 nvestigated this hypothesis in a prospective placebo-controlled study of treated patients with hypert

216 We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully huma

217 e, randomized, double-blinded, double-dummy, placebo-controlled study of vitamin D(3) supplementation

218 Recent randomized placebo-controlled studies on chronic laryngitis, cough,

219 We conducted a 3-month, double-blind, placebo-controlled study on the effects of donepezil in

220 the initial focal point being the ethics of placebo-controlled studies; only a handful of reports, h

221 zed, single-centre, double-blind, crossover, placebo-controlled study, partial responders taking opti

222 In this phase 2A double-blind, randomised, placebo-controlled study, patients aged 18 years or olde

223 ot investigation followed by a double-blind, placebo-controlled study, patients with allergic rhiniti

224 In addition, vehicle- or placebo-controlled studies predominate over head-to-head

225 20-wk phase 3 double-blind, randomized, and placebo-controlled study received subsequently 1 mg/kg o

226 Well designed, randomized, placebo-controlled studies show that niacin prevents car

227 Recent double-blind, randomized, placebo-controlled studies suggest that antioxidant vita

228 To date, there have been no randomized, placebo-controlled studies supporting the efficacy of an

229 Randomized, double-blind, placebo-controlled studies that evaluated beta-blockers

230 and ARIES-2 trials were the pivotal 12-week, placebo-controlled studies that led to the regulatory ap

231 ucted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess

232 This was the first placebo-controlled study that also controlled for the co

233 We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and

234 o 1a was a subject-blinded, dose-escalation, placebo-controlled study that randomized 85 healthy volu

235 Here, we report a double-blind, placebo-controlled, study that examined specific effects

236 In this randomized, double-blind, placebo-controlled study the safety, tolerability, and c

237 In a randomized, placebo-controlled study, the safety and immunogenicity

238 This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over

239 y QOL-B-RSS, suggesting a continued need for placebo-controlled studies to establish the clinical ben

240 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect w

241 nducted a 6-month, randomized, double-blind, placebo-controlled study to assess safety, tolerability,

242 This is the first placebo-controlled study to assess the effects of chroni

243 We conducted a randomized, double-blind, placebo-controlled study to assess whether raltegravir i

244 This is the first randomized, placebo-controlled study to demonstrate that antimycobac

245 We performed a randomized, placebo-controlled study to determine its effects on sym

246 We performed a placebo-controlled study to determine whether a delayed-

247 We conducted a double-blind, randomized, placebo-controlled study to evaluate the effect of gallo

248 A I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and sa

249 We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of tel

250 A randomized, double-blind, placebo-controlled study to evaluate the impact of oral

251 We conducted a phase 2, double-blind, placebo-controlled study to evaluate the safety and anti

252 Here, we report the first double-blind placebo-controlled study to examine the effects of MDMA

253 We conducted a single-blind, placebo-controlled study to examine the effects of torce

254 We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone

255 performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of

256 ed a parallel, double-blind, randomized, and placebo-controlled study to investigate the effect of ph

257 en season were randomized in a double-blind, placebo-controlled study to receive 300IR 5-grass pollen

258 rhinitis were randomized in a double-blind, placebo-controlled study to receive 500 index of reactiv

259 were enrolled in a randomized, double-blind, placebo-controlled study to receive IV methylprednisolon

260 In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asi

261 were enrolled into a randomized double-blind placebo-controlled study using 4 weeks of slow-release m

262 We performed a randomized, placebo-controlled study using C1-INH in highly sensitiz

263 A randomized, double-blind, placebo-controlled study was conducted among 44 subjects

264 IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in

265 A double-blind, randomized, crossover, placebo-controlled study was conducted in 10 HET and 15

266 A prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects f

267 se 2, multicenter, randomized, double-blind, placebo-controlled study was conducted in 138 patients w

268 A single-blind, randomized, placebo-controlled study was conducted in patients infec

269 A randomized, double-blind, placebo-controlled study was conducted in patients with

270 This double-blind, placebo-controlled study was conducted to assess the eff

271 ternational, randomized (2:1), double-blind, placebo-controlled study was conducted to compare comple

272 h factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andex

273 This randomized, double-blind, placebo-controlled study was designed to compare humoral

274 This three-stage randomised, double-blind, placebo-controlled study was done at 59 clinical sites i

275 this prospective, randomized, double-blind, placebo-controlled study was to compare the effect of de

276 he purpose of this double-blind, randomized, placebo-controlled study was to determine the impact of

277 f this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the

278 The aim of this randomized, double-blind, placebo-controlled study was to test the hypothesis that

279 This randomized, double-blind, placebo-controlled study was undertaken to examine the s

280 In a double-blind, placebo-controlled study we examined approach-avoidance

281 In this exploratory, double-blind, placebo-controlled study we recruited male patients (>/=

282 In this double-blinded, placebo-controlled study, we addressed the role of NGF/N

283 this multicenter, randomized, double-blind, placebo-controlled study, we assessed larazotide acetate

284 In our 6 week, randomised, double-blind, placebo-controlled study, we enrolled adults (aged >/=40

285 In this prospective, blinded, placebo-controlled study, we evaluated the hypothesis th

286 this multicenter, double-blind, randomized, placebo-controlled study, we examined whether treatment

287 se 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patie

288 In this double-blind, placebo-controlled study, we randomly assigned 31 patien

289 In this randomized, double-blind, placebo-controlled study, we randomly assigned 32 HSCT r

290 In this double-blind, placebo-controlled study, we randomly assigned 5362 pati

291 In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patie

292 In this phase 3, multicentre, randomised, placebo-controlled study, we randomly assigned adults wi

293 In this international, double-blind, placebo-controlled study, we randomly assigned patients

294 In this double-blind, placebo-controlled study, we randomly assigned subjects

295 icentre, parallel, randomised, double-blind, placebo-controlled study, we recruited patients aged 18-

296 In a placebo-controlled study, we used arterial spin labeling

297 In placebo-controlled studies with anti-IgE, many patients

298 We conducted a multicenter, randomized, placebo-controlled study with a 2-week single-blind run-

299 were enrolled in a double-blind, randomized, placebo-controlled study with pexacerfont (300 mg/day fo

300 sessed this hypothesis via a double-blinded, placebo-controlled study with the dopamine receptor agon